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Background: Vinflunine is recommended in the European guideline for the treatment of advanced or metastatic
urothelial cell carcinoma (UCC) after failure of platinum-based therapy.
Methods: This prospective, non-interventional study investigated the safety and efficacy of vinflunine in
platinum-pretreated UCC patients in routine clinical practice. Data were prospectively collected on patients with
advanced or metastatic UCC undergoing vinflunine treatment in 39 German hospitals and medical practices.
Dosing of vinflunine, tumor assessments and concomitant medications followed physician’s routine clinical
practice. Primary endpoints were toxicity and assessment of vinflunine treatment modalities. Secondary aims
included overall response rate (ORR), overall survival (OS) time and a prognostic risk-model.
Results: Seventy-seven platinum-pretreated patients were recruited. Vinflunine was predominantly administered
as second-line (66 %) therapy or in subsequent treatment lines (21 %). One third of the patients received at least six
cycles of vinflunine and the average number was 4.7 cycles. A vinflunine starting dose of 320 mg/m2 was chosen in
48 % of patients and 280 mg/m2 in 39 %. Grade 3/4 toxicities were leucopenia 16.9 %, anemia 6.5 %, elevated liver
enzymes 6.5 % and constipation 5.2 %. ORR was 23.4 % and OS was 7.7 (CI 4.1 to 10.4) months. Patients with zero, one,
two or≥ three risk factors displayed a median OS of 18.2, 9.5, 4.1 and 2.8 months, respectively (p = 0.0005; HR = 1.82).
Conclusion: Vinflunine delivers a meaningful benefit to an unselected population of advanced platinum-pretreated
UCC patients managed in routine clinical practice.
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Metastatic urothelial cell carcinoma (UCC) responds
well to chemotherapy. With cisplatin-based regimens a
median overall survival (OS) of 12.5–15.5 months can
be reached in the first-line setting [1, 2]. However, there
were limited therapeutic options for patients who subse-
quently failed cisplatin-based therapy.
When vinflunine was approved by the European Medi-
cines Agency (EMA) in 2009, it was the first chemotherapy* Correspondence: margitta.retz@lrz.tum.de
1Urologische Klinik und Poliklinik, Technische Universität München,
Ismaninger Str. 22, 81675 Munich, Germany
Full list of author information is available at the end of the article
© 2015 Retz et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/to be registered for use following failure of platinum-based
treatment. Vinflunine is a novel microtubule inhibitor and
has shown improved patient outcomes in a multicenter,
placebo-controlled phase III trial [3]. In this study, 370 pa-
tients with metastatic UCC who failed first-line platinum-
based chemotherapy were randomized 2:1 to receive ei-
ther vinflunine plus best supportive care (BSC) or BSC
alone. In the intent-to-treat (ITT) population median OS
was 6.9 months and 4.6 months in the vinflunine plus
BSC and BSC arm, respectively. Though this difference
did not reach statistical significance vinflunine treatment
correlated with increased survival [4]. The final analysis
on the eligible population demonstrated a median OS of
6.9 months for the vinflunine group versus 4.3 months forle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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risk of death (p = 0.0227). Overall response rate (ORR),
disease control rate (DCR), and progression free survival
(PFS) were all statistically significant in favor of vinflunine
[3]. Subsequently vinflunine has been recommended as
the standard of care in these patients in the EAU guide-
lines [5].
Although vinflunine was efficacious in the randomized
phase III trial, patients under study conditions may not
fully reflect actual clinical practice as they are selected
and their therapy management is strictly protocol-
driven. Consequently, the use of vinflunine in routine
clinical practice might not fully translate into similar
outcomes to the registration study data.
The objective of this observational study was to exam-
ine the efficacy and toxicity of vinflunine as well as the
adverse events (AE) management in routine clinical
practice, where unselected patients were treated following
the registered marketing authorization across a prospect-
ive, multicenter and non-interventional study (NIS). Fur-
thermore, a prognostic risk-model was evaluated for the
NIS population.
Methods
In compliance with the German Drug Law (AMG) the
non-interventional study was reported to the competent
authority and approved by the ethics committee of the
scientific leader (ethics committee of the Technische
Universitaet München, Germany). The prospective NIS
included patients with histologically confirmed locally
advanced or metastatic UCC who experienced failure of
a prior platinum-based chemotherapy. Patients had to
have an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0 or 1, as well as an adequate
hematologic, hepatic and renal (calculated clearance of
creatinine > 20 ml/min) function. Main exclusion cri-
teria were brain metastases and a life expectancy <
2 months. A total of 77 patients were enrolled from 15
urological and 3 oncological hospitals (42 and 6 pa-
tients, respectively) as well as from 14 urological and 7
oncological practices (20 and 9 patients, respectively)
throughout Germany. Initially it was planned to recruit
200 patients but the study was discontinued before
reaching the planned sample size due to slow recruit-
ment. The NIS was conducted according to the provi-
sions as laid down in the Declaration of Helsinki and
registered on clinicaltrials.gov (NCT01103544). All pa-
tients were required to sign written informed consent
before any documentation of patient data could take
place and the decision to treat with vinflunine had to be
drawn independently from the study (i.e. before the de-
cision to participate in this NIS).
Owing to the non-interventional design of this trial,
physicians were not instructed on any treatment decisionsincluding dosages of vinflunine, tumor assessments, AE-
management and concomitant medications. An antiemetic-
and laxative prophylaxis was recommended in accordance
to the routine clinical practice. The planned observation
period was limited to a maximum of six cycles of vinflu-
nine. The patient's final documentation took place 30 days
after the last administration of vinflunine or after the sixth
administration. Data were prospectively collected in stan-
dardized electronic case report forms on patient char-
acteristics (performance status [6]), AE according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) v3 criteria,
vinflunine dosages and number of administered cycles.
Furthermore, tumor assessments and co-medication or
dietary measures to prevent constipation and nausea
were documented. Patients were additionally followed
for survival information. Missing or inconsistent data
were identified by central data review and clarified by
corresponding data queries.
Primary endpoints of this study were the frequency
of AE according to the NCI-CTCAE v3 criteria as well
as the assessment of vinflunine treatment modalities
(e.g. dosage, duration, concomitant medication) with
the aim of a descriptive analysis. Secondary aims in-
cluded the ORR and the median OS. The protocol sug-
gested that the tumor response is assessed at least once
during treatment (i.e. between the first chemotherapy
visit and the final visit) by imaging and evaluated ac-
cording to the RECIST 1.1 criteria. Additionally, prog-
nostic factors for advanced UCC receiving second-line
systemic therapy were evaluated based on the prognostic
stratification model by Sonpavde et al. [7] The model
defines four risk factors: liver metastases, ECOG PS,
hemoglobin (Hb) value and time from prior chemotherapy
(TFPC).
Explorative methods were used for the analysis of the
collected data. All collected parameters were analyzed
descriptively. Arithmetic means, standard deviations and
95 % confidence intervals (CI) were calculated for continu-
ous characteristics. Differences in baseline parameters were
tested by one-way ANOVA (analysis of variance). Time-
based efficacy parameters were presented as Kaplan-Meier
curves and subject to the log-rank test for significance.
For the risk factor model analysis, patients were assigned
to the lower risk group if values were missing to perform
the analysis on the full patient population (statistical sig-
nificance was confirmed by leaving out patients with miss-
ing values). Statistical analysis was performed on the basis
of SAS version 9.2.
Results
From 08/2010 to 09/2011, 77 patients were evaluable on
an intent-to-treat (ITT) basis from 39 German centers.
The median age of the ITT group was 67 (range 39–80)
Table 2 Treatment regimens prior to vinflunine (ITT-population:
n = 77)
Previous treatment % patients
Gemcitabine + cisplatin 82
Gemcitabine + carboplatin 12





Patients might have had more than one previous therapy. Therapies were
listed if > 3 % of the patients were treated with the regimen. Other regimens
include (with decreasing frequency): methotrexate/vinblastine/doxorubicin/
cisplatin (conventional and dose dense), docetaxel,
cisplatin/paclitaxel, carboplatin/paclitaxel
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45.5 % and 54.5 % of all patients, respectively. Visceral
involvement was found in 59.7 % of patients.
Previous platinum-based chemotherapy was adminis-
tered in (neo)-adjuvant or palliative intentions. Accord-
ingly, vinflunine was scheduled as first line treatment for
12 % of the patients following (neo)-adjuvant platinum-
based regimens. Notably, vinflunine was predominantly
administered as second-line palliative therapy in 66 % of
all patients, as third-line in 18 % and as further treat-
ment line in 3 %. Focusing on different pre-treatment
schedules, 82 % of all patients were pretreated with the
combination of gemcitabine and cisplatin, 12 % with
gemcitabine and carboplatin and 12 % received gemcita-
bine and paclitaxel (Table 2). Monotherapy with differ-
ent antineoplastic agents such as gemcitabine, cisplatin
or paclitaxel was performed in 17 % of the study group.
About half of the patients were treated with a starting
dose of 320 mg/m2 and the other half with 280 mg/m2
or less. Patients with the higher starting dose were youn-
ger (p = 0.03) (Table 1). The median number of vinflu-
nine cycles was four (mean 4.7) cycles and one-third of
the patients received at least six cycles (Fig. 1). A con-
comitant antiemetic therapy was given in 65 patients
(84.4 %). The most commonly used agents were dexa-
methasone (46.2 %), granisetron (44.6 %) and/or meto-
clopramide (23.1 %); these were predominantly given inTable 1 Patient demographics and clinical characteristics
(ITT-population: n = 77)
Overall Starting dose Starting dose
320 mg/m2 ≤280 mg/m2
n = 77 n = 37 n = 40 *
Female 14 (18.2 %) 6 (16.2 %) 8 (20.0 %)
Male 63 (81.1 %) 31 (83.3 %) 32 (80.0 %)
Median age in years (range) 67 (39–80) 66 (39–77) 70 (51–80)
≥70 y 32 (41.6 %) 12 (32.4 %) 20 (50.0 %)
ECOG PS
0 35 (45.5 %) 18 (48.6 %) 17 (42.5 %)
1 42 (54.5 %) 19 (51.4 %) 23 (57.5 %)
Visceral involvement 46 (59.7 %) 23 (62.2 %) 23 (57.5 %)
Liver metastases† 17 (22.1 %) 6 (16.2 %) 11 (27.5 %)
TFPC < 6 months‡ 45 (58.4 %) 19 (51.4 %) 26 (65.0 %)
Mean Hb in g/dL§ 11.2 11.6 10.9
Hb < 10 g/dL§ 13 (16.9 %) 5 (13.5 %) 8 (20.0 %)
ECOG: Eastern Cooperative Oncology Group; PS: performance status; TFPC:
time from prior chemotherapy; Hb: hemoglobin
*n(280 mg/m2) = 30; n(<280 mg/m2) = 10
†information missing for 4 patients in the 320 mg/m2 group and 8 patients in
the ≤ 280 mg/m2 group
‡information missing for 6 patients in the 320 mg/m2 group and 2 patients in
the ≤ 280 mg/m2 group
§information missing for 6 patients in the 320 mg/m2 group and 2 patients in
the ≤ 280 mg/m2 group; ITT: intent-to-treata prophylactic intent (95.4 %). Co-medication to prevent
constipation was administered in 55 patients (71.4 %).
Commonly used laxative agents were macrogol (65.5 %)
and/or lactulose (14.5 %), usually given prophylactically
(87.3 %).
A total of 272 AEs were documented in 55 (71.4 %)
patients, of which 177 AEs were assessed as potentially
related to vinflunine. About half of the patients (49.4 %)
experienced at least one AE considered to be related to
vinflunine. The most frequent treatment-related AEs
considering all grades of intensity were hematological
toxicities (Table 3): leucopenia (22.1 %), anemia (16.9 %)
and thrombocytopenia (7.8 %). Hematological adverse
events of grade ≥ 3 mainly included leucopenia (16.9 %)
and anemia (6.5 %). Only one patient (1.3 %) experienced
neutropenic infection. The most commonly reported non-
hematological toxicities grade ≥ 3 were elevated liver en-
zymes (6.5 %) and constipation (5.2 %).
To evaluate the ORR, 72 patients (93.5 %) underwent
at least one tumor assessment (median 2, range 1–7) by
imaging methods. The ORR was 23.4 % (95 % CI, 14.5 %


















treatment cycles with vinflunine
Fig. 1 Number of vinflunine treatment cycles (ITT- population:
n = 77); documentation was limited to a maximum of six vinflunine
treatment cycles
Table 3 Most common treatment-related adverse events
(ITT-population: n = 77)
All grades Grades ≥ 3*
N % N %
Any event 38 49.4 23 29,9
Leukopenia 17 22.1 13 16.9
Anemia 13 16.9 5 6.5
Thrombocytopenia 6 7.8 1 1.3
Neutropenia 2 2.6 1 1.3
Elevated liver enzymes‡ 16 20.8 5 6.5
Fatigue 12 15.6 1 1.3
Pain§ 10 13.0 3 3.9
Constipation 9 11.7 4 5.2
Nausea 9 11.7 2 2.6
Constitutional symptoms 4 5.2 3 3.9
Infection† 3 3.9 3 3.9
Mucositis 3 3.9 0 0.0
Vomiting 2 2.6 2 2.6
Neutropenic infection 1 1.3 1 1.3
Adverse events occurring in at least 3 patients are listed. For completeness
neutropenia and vomiting have been added
*3 potentially treatment-related deaths were reported: infection (relation
possible), infection (relation likely), hypoxia (relation possible)
‡Summarizing elevated alanine-aminotransferase (ALT), aspartate-
aminotransferase (AST), alkaline phosphatase and
gamma-glutamintranferase (GGT)
§Pain in abdomen, extremity, head, joint or stomach
†Infections with normal absolute neutrophil count (ANC)
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response. More than half of the patients (53.2 %) reached
disease control (DC) during treatment with vinflunine
(Table 4). Investigating survival data, 54 of 77 patients
(70.1 %) died within the study period. Median observation
time was 4.6 (0.4–23.8) months. The median OS time was
7.7 months (95 % CI, 4.1 months to 10.4 months) (Fig. 2A).
Stratifying OS by vinflunine starting dose, patients receiv-
ing the recommended vinflunine dose of 320 mg/m2
achieved significantly longer median OS with 10.4 months
compared to patients treated with starting doses ≤
280 mg/m2 with a median OS of 4.5 months (p = 0.016).
Data from the NIS were analyzed using the risk factor
model established by Sonpavde and coworkers [7]. This
model defines four risk factors; presence of liver metas-
tases, ECOG PS = 1, mean Hb value < 10 g/dL andTable 4 Efficacy results (ITT: intent-to-treat-population: n = 77)
No. of patients % 95 % CI, %
Complete response 4 5.2
Partial response 14 18.2
Stable disease 23 29.9
Objective response rate 18 23.4 14.5-34.4
Disease control rate 41 53.2 41.5-64.7TFPC < 6 months. Median OS inversely correlated with
the number of risk factors: patients with zero, one, two
or ≥ three risk factors displayed a median OS time of
18.2 months, 9.5 months, 4.1 months and 2.8 months,
respectively (p = 0.0005; HR = 1.82) (Fig. 2B). Both pres-
ence of liver metastases and ECOG PS 1 were independ-
ent prognostic factors for shorter survival in a univariable
analysis (HR =4.330, p < 0.0001 and HR= 1.820, p = 0.0310,
respectively). In a multivariate analysis, the presence of
liver metastases was the strongest risk factor influen-
cing OS (p < 0.0001).Discussion
Non-interventional studies (NIS) are highly valuable for
guiding clinical practice. On the one hand they may
more accurately reflect the efficacy and safety of treat-
ment strategies under “real world” conditions; on the
other hand NIS may give insights into how therapies
might be applied more effectively. Although NIS provide
useful supplementary information, they cannot substi-
tute for the data from randomized controlled trials. The
lack of control over patient management, the specifica-
tion of interventions as well as timing and type of tumor
assessments results in the facts that NIS cannot deliver
precise progression-free-survival data, efficacy data must
be interpreted with caution and, furthermore, adverse
effects might be underestimated due to less frequent
visit procedures; nevertheless severe AEs are usually
reported.
Despite the limitations inherent in NIS, this trial
clearly demonstrates that the efficacy and safety of vin-
flunine therapy - as observed in controlled, randomized
studies - is transferable in the daily routine of clinical
practice [3, 8, 9]. Particularly the feasibility of vinflunine
treatment is not limited to hospitals since more than
one third of the NIS patients were treated in medical
practices. The high numbers and the diversity of recruit-
ing centers indicate that vinflunine treatment is manage-
able in various and different settings.
Although vinflunine is approved by the EMA as
chemotherapy after failure of platinum-based treatment,
20 % of the patients were scheduled for third- and
fourth-line therapy. Nevertheless, the majority of the pa-
tients (66 %) received vinflunine as second-line palliative
treatment, which is comparable to the French observa-
tional study by Medioni and coworkers [10].
Considering that a maximum of six cycles was proto-
colled in this study, the average cycle number of 4.7 cy-
cles and the fact that one-third of the patients received
at least six cycles suggests a good tolerability of vinflunine.
Furthermore, 48.1 % and 39.0 % of the NIS patients received
a vinflunine starting dose of 320 mg/m2 or 280 mg/m2, re-
spectively. These data confirm an equivalent study drug
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Fig. 2 Overall survival (ITT: intent-to-treat OS: overall survival-population: n = 77); (a) of the overall population (solid line), patients with a starting
dose of 320 mg/m2 (broken line) and≤ 280 mg/m2 (dotted line); (b) according to prognostic factors defined by Sonpavde et al.; overall survival is
displayed according to the number of risk factors: 0 (orange), 1 (green), 2 (blue), 3/4 (red) risk factors; risk factors were: presence of liver metastasis,
ECOG = 1, Hb value < 10 g/dL, time from prior chemotherapy < 6 months; RF: risk factor; ITT: intent-to-treat; OS: overall survival
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coworkers [3].
One primary endpoint of this study was the frequency
of adverse events according to the NCI-CTCAE v3.
Hematological toxicity was low in the NIS population
with grade 3/4 neutropenia of 1.3 % and leucopenia
16.9 % in contrast to 50 % neutropenia in the random-
ized controlled phase III study [3]. Retrospective multi-
center studies performed in Spain and France displayed
incidences of 12.8 % and 17.2 % [11, 10], respectively.
Notably, neutropenic infections were reported in 1.3 %
of the NIS patients compared to 6.0 % in the trial from
Bellmunt and coworkers [3]. The incidence of gastro-
intestinal toxicities was low with grade 3/4 constipation
in 5.2 % and nausea and vomiting each in 2.6 % of the
patients. These low gastrointestinal toxicities were pos-
sibly achieved because more than 84 % and 71 % of the
NIS patients received the recommended antiemetic and
laxative prophylaxis, respectively. The gastrointestinal
tolerability was slightly better compared to the results of
the prospective phase-III trial. The incidence of consti-
pation of 11.7 % was in line with the data of the Spanish
and French retrospective studies [10, 11]. These observa-
tions across three countries could suggest that an in-
creased experience in the drug use could play a role in
the safety findings with physicians learning how to
optimize side effect prophylaxis in routine practice.
The efficacy results in the NIS trial are consistent with
the previous data of the prospective phase III study [3].
About one-quarter of the patients (23.4 %) responded to
vinflunine treatment. More than half of the patients
(53.2 %) reached at least DC, which seems to be a repre-
sentative result compared to other vinflunine trials witha DC rate of 41.1 % in the randomized phase III trial as
well as 51 % and 65.7 % in both retrospective studies [3,
10, 11]. The median OS time was 7.7 months for the
whole NIS group, which is slightly higher compared to
the survival results from the phase III trial with
6.9 months [3, 4]. Similar results have been found in
retrospective studies with a median OS time between
8.1 months and 10.0 months [10–12]. Of note, a vinflu-
nine starting dose of 320 mg/m2 resulted in a better
outcome regarding median OS time (10.4 months) com-
pared to starting doses of ≤ 280 mg/m2 (4.5 months).
The population was younger in the 320 mg/m2 starting
dose group compared to the group with lower initial vin-
flunine doses (median age 66 vs. 70 years, respectively).
Patients with lower vinflunine starting dose tended to
have more risk factors at baseline (liver metastases,
TPFC, Hb < 10 g/dl) though the difference was not sig-
nificant. In summary, the NIS analysis strongly recom-
mends an optimal vinflunine starting dose of 320 mg/m2
as long as there are no medical restrictions.
Data from this NIS were analyzed according to the
prognostic risk factor model from Sonpavde and co-
workers [7]. On the basis of pooled data from seven
prospective phase II trials of patients with advanced
platinum-pretreated UCC, the risk factor model strati-
fied four prognostic factors including Hb level, perform-
ance score (ECOG-PS), presence of liver metastases and
TFPC. The analysis from Sonpavde et al. [7] reported a
median OS of 12.2 months, 6.7 months, 5.1 months and
3.0 months for patients with zero, one, two and three to
four risk factors, respectively. Our non-interventional
study resulted in similar differences in median OS times
with 18.2 months, 9.5 months, 4.1 months and 2.8 months
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of the data collected under routine clinical conditions.
The risk factor model could help to define the individual’s
prognosis more accurately. Nevertheless, individual pa-
tients with multiple risk factors could still benefit from
vinflunine treatment. Furthermore, the model may im-
prove the interpretation and setup of clinical trials.
Conclusion
This prospective non-interventional study confirmed
that vinflunine delivers a meaningful benefit to an unse-
lected population of advanced platinum-pretreated UCC
patients managed in routine clinical practice. A systematic
gastrointestinal prophylaxis is strongly recommended to
achieve a good safety profile. The vinflunine starting dose
of 320 mg/m2 was most efficacious with a median OS of
10.4 months and should therefore be considered in all eli-
gible patients. This study adds further support to the EAU
recommendation for the use of vinflunine as second-line
therapy in advanced UCC after failure of platinum-based
treatment.
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